- Home
- CNEY vs MTNB Comparison
CNEY vs MTNB Comparison
Compare CNEY & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNEY | MTNB |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.2M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CNEY | MTNB |
|---|---|---|
| Price | $0.58 | $0.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.2M | 821.7K |
| Earning Date | 02-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.31 | $0.24 |
| 52 Week High | $2.95 | $3.09 |
Technical Indicators
Market Signals| Indicator | CNEY | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 25.67 |
| Support Level | $0.58 | N/A |
| Resistance Level | $1.05 | $0.66 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 25.72 | 2.04 |
Price Performance
Historical ComparisonAbout CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.